Clinical Trial Search

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants

Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants

Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants

Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants

Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…

Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001

Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…

Primary: Event-free Survival — 64.9; 70 percentage of participants

Primary: Event Free Survival. EFS — 66.0 percentage of participants EFS at 3 yrs3

Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants

Primary: Number of Patients With Complete Remission — 3 participants

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Response Rate (RR) — 11 Participants

Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants

Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…

Primary: Complete Remission — 52 percentage of participants

Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability

Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability

Primary: Complete Response Rate — 89 percentage of patients

Primary: Complete Response (CR) Rate — 28 percentage of participants

Primary: Complete Response (CR or CRi) — 0 proportion of participants

Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants

Primary: MTD of VSLI — 2.25 mg/m2

Primary: Complete Remission — 10 participants

Primary: Overall Survival at One Year — 19 Participants

Primary: Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy — 72.2; 63 Percentage of participants

Primary: Number of Patients That Experienced DLT During Cycle 1 of Therapy — 3; 3; 5; 3 Participants

Primary: Disease Free Survival — 1.7 years